03 Sep 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Australia based-Genetic Technologies filed a patent infringement suit in respect of its non-coding DNA technologies against Reproductive Genetics Institute in the US District Court, for the Northern District of Illinois, Eastern Division. Further details regardign the suit are yet to be disclosed.
While Genetic Technologies is diagnostic company engaged in commercializing genetic testing, non‐coding DNA and product patenting, Reproductive Genetics Institute (RGI) is a pioneer in the fields of preimplantation genetic diagnosis (PGD) and prenatal testing.
Genetic Technologies is focused on the commercialization of its patent portfolio through an active out‐licensing program and the global expansion of its oncology and cancer management diagnostics assets.
Its US subsidiary, Phenogen Sciences, offers predictive testing and assessment tools to help physicians proactively manage women's health. Phenogen's lead product, BREVAGen, is a first in class, clinically validated risk assessment test for non‐familial breast cancer.